drugset / Trial / NCT01919450

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

NCT01919450

Phase 4 Completed 80 enrolled Timothy M. Bateman, MD
RandomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection. It is anticipated that there will be no or minimal difference between the four delay times.

Timeline

Start
2013-07
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Regadenoson Diagnostic / imaging agent

Indications

No indication recorded.